Valuation : Avacta Group Plc

Market Cap 323M 437M 375M 354M 603M 41.74B 609M 4.22B 1.62B 21.17B 1.64B 1.6B 67.25B P/E 2026 *
-10.7x
P/E 2027 * -12.4x
Enterprise Value 319M 432M 372M 351M 597M 41.31B 602M 4.18B 1.61B 20.95B 1.62B 1.59B 66.55B EV / Sales 2026 *
116x
EV / Sales 2027 * 42.1x
Free-Float
97.08%
Yield 2026 *
-
Yield 2027 * -

Last Transcript : Avacta Group Plc

Manager TitleAgeSince
Chief Executive Officer 56 01/04/2024
Director of Finance/CFO 51 22/01/2025
Chief Tech/Sci/R&D Officer - 09/02/2026
Director TitleAgeSince
Director/Board Member 60 03/02/2020
Director/Board Member 71 17/08/2021
Director/Board Member 56 18/03/2022
Change 5-day change 1-year change 3-year change Capi.($)
-0.25%-1.36%+44.08%+102.76% 68.24B
+0.02%-4.30%+30.60%+73.93% 62.23B
-1.18%+0.47%-12.78%+384.69% 27.8B
-1.89%-5.29%+29.39%+9.09% 24.86B
-1.76%-6.30%-4.55%-19.75% 24.22B
-0.36%-5.19%+17.75%-20.95% 19.36B
-1.86%-2.22%+202.03%+353.89% 17.28B
-2.15%-4.90%-5.25%+495.90% 14.46B
-1.54%-2.88%+52.33%+159.75% 14.23B
Average -1.22%-3.30%+39.29%+171.03% 30.3B
Weighted average by Cap. -0.86%-3.10%+35.51%+136.45%

Financials

2026 *2027 *
Net sales 2.74M 3.71M 3.19M 3.01M 5.13M 355M 5.18M 35.87M 13.8M 180M 13.94M 13.63M 572M 8.12M 10.98M 9.44M 8.91M 15.17M 1.05B 15.31M 106M 40.84M 533M 41.24M 40.34M 1.69B
Net income -28.92M -39.12M -33.64M -31.74M -54.06M -3.74B -54.55M -378M -145M -1.9B -147M -144M -6.03B -23.64M -31.98M -27.5M -25.95M -44.19M -3.06B -44.59M -309M -119M -1.55B -120M -117M -4.93B
Net Debt -3.33M -4.51M -3.88M -3.66M -6.23M -431M -6.29M -43.6M -16.78M -219M -16.94M -16.57M -695M 18.99M 25.69M 22.1M 20.85M 35.51M 2.46B 35.83M 248M 95.56M 1.25B 96.49M 94.38M 3.96B
Logo Avacta Group Plc
Avacta Group plc is a United Kingdom-based life sciences company developing peptide drug conjugates (PDC) targeting anti-tumor payloads directly to the tumor. The Company is focused on the development of its proprietary preCISION technology platform. The preCISION platform is a highly specific substrate for fibroblast activation protein (FAP) which is upregulated in most solid tumors compared with healthy tissues. The preCISION platform harnesses this tumor-specific protease to cleave preCISION peptide drug conjugates and preCISION antibody/Affimer drug conjugates in the tumor microenvironment, thus releasing active payload in the tumor and reducing systemic exposure and toxicity. Its lead program, AVA6000, is a clinical-stage asset which is a preCISION-enabled form of doxorubicin. AVA6103, the Company’s second program, is a preCISION-enabled PDC comprised of the preCISION peptide linked to exatecan, the most potent topoisomerase I (topo I) inhibitor in clinical development.
Employees
-
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
-
40% Discount: Identify Tomorrow's Best Investments With The Best Subscriber-Only Tools!
d
:
:
SEIZE THE OFFER!